Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPAGT1 | Q9H3H5 | 6/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618331 | 0.92 | DPAGT1 (0.61) | DPAGT1 | |
| SCHEMBL14598996 | 0.91 | DPAGT1 (0.63) | DPAGT1 | |
| SCHEMBL14628971 | 0.90 | DPAGT1 (0.61) | DPAGT1 | |
| SCHEMBL14598995 | 0.90 | DPAGT1 (0.63) | DPAGT1 | |
| SCHEMBL14598997 | 0.90 | DPAGT1 (0.63) | DPAGT1 | |
| SCHEMBL14598994 | 0.90 | DPAGT1 (0.65) | DPAGT1 | |
| SCHEMBL14599043 | 0.89 | DPAGT1 (0.61) | DPAGT1 | |
| SCHEMBL14599013 | 0.89 | DPAGT1 (0.61) | DPAGT1 | |
| SCHEMBL14599054 | 0.89 | DPAGT1 (0.62) | DPAGT1 | |
| SCHEMBL14599049 | 0.89 | DPAGT1 (0.62) | DPAGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. | 2009-11-12 | — | — | US | disclosed |
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | TTPA, PHOSPHO1, CAPG | DPAGT1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.